


Stereoselective Synthesis of Constrained Oxacyclic Hydroxyethylene Isosteres of Aspartic Protease Inhibitors: Aldol and Mukaiyama Aldol Methodologies for Branched Tetrahydrofuran 2-Carboxylic Acids

Stephen Hanessian,*,[†] Yihua Hou,[†] Malken Bayrakdarian,[†] and Marina Tintelnot-Blomley[‡]

Department of Chemistry, Université de Montréal, C.P. 6128, Station Centre-ville, Montréal, P.Q., H3C 3J7, and Novartis Institutes of Biomedical Research, Novartis Pharma AG, Postfach CH-4002, Basel, Switzerland

stephen.hanessian@umontreal.ca

Received April 14, 2005



The synthesis of diastereomeric 3-substituted-tetrahydrofuran 2-carboxylic acids in enantiopure form was achieved relying on aldol condensations of N-substituted α -amino aldehydes with enolates and enol silyl ethers of γ -butyrolactone. Catalytic YbFOD leads to a high yield of a *syn/syn-* α amino alcohol isomer. This was used as a constrained THF subunit in the synthesis of a peptidomimetic intended as an inhibitor of the enzyme BACE1, which is implicated in the cascade of events leading to plaque formation in Alzheimer's disease.

Introduction

The advent of structure-based design of enzyme inhibitors has instigated extensive studies on conceptually novel approaches to peptidomimetic motifs.¹ One of the more commonly used replacements for a scissile bond in a specific dipeptide portion of a peptidic inhibitor is the hydroxyethylene isostere, especially in conjunction with aspartic proteases.² For example, the potent synthetic heptapeptide inhibitor of β -secretase (BACE1, memapsin-2) OM99-2³ has such a hydroxyethylene subunit as part of its structure (Figure 1). The length of this subunit

(2) For excellent reviews, see: (a) Cooper, J. B. Curr. Drug Targets
2002, 3, 155. (b) Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem.
2000, 43, 305. (c) Bender, S. L.; Babine, R. Chem. Rev. 1997, 97, 1359.

(3) (a) Hong, L.; Koelsch, G.; Lin, X.; Wu, W. S.; Terzyan, S.; Ghosh,
 A. K.; Zhang, X. C.; Tang, J. Science 2000, 290, 150. See also: (b) Hong,
 L.; Turner, R. T., III; Koelsch, G.; Shin, D.; Ghosh, A. K.; Tang, J. Biochemistry 2002, 41, 10963.

10.1021/jo050749y CCC: \$30.25 © 2005 American Chemical Society Published on Web 07/21/2005




FIGURE 1. Tang–Ghosh inhibitor OM99-2 of β -secretase (BACE1) and proposed P₁' constrained oxacyclic hydroxyethylene isosteres.

corresponds to that of a Leu-Ala dipeptide, in which the central amide bond is replaced by an S-hydroxyethylene isostere. Thus, OM99-2 can be considered as a pseudo-octapeptide encompassing a central unnatural γ -amino acid. BACE1 is an important membrane-bound enzyme that initiates the formation of β -amyloid peptide from the amyloid precursor protein. A cascade of events follow, ultimately leading to plaque formation in the brain.⁴ The enzyme has been considered as an ideal target for small

 $[\]ast$ To whom correspondence should be addressed. Phone: (514) 343-6738. Fax: (514) 343-5728.

[†] Université de Montréal.

[‡] Novartis Pharma AG.

⁽¹⁾ For selected reviews, see: (a) Ripka, A. S.; Rich D. H. Curr. Opin. Chem. Biol. 1998, 2, 44. (b) Gante, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699. (c) Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 53, 12789. (d) Gillespie, P.; Cicarello, J.; Olson, G. L. Biopolymers 1997, 43, 101. (e) Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action; Academic: San Diego, CA, 1992.

molecule inhibitors, with the objective of developing a drug for Alzheimer's disease.⁵ X-ray crystal structures of OM99-2 and close derivatives thereof bound to BACE1^{3,6} show the critical role of the hydroxyl group at the P₁ site for interaction with the two Asp residues at the catalytic site. Extensive SAR studies on OM99-2 has instigated much interest in the synthesis of smaller, nonpeptidic inhibitors of the enzyme.^{6,7}

We have previously reported on the design and synthesis of a number of prototypical enzyme inhibitors in therapeutically relevant areas.⁸ Herein we report on our results of the stereoselective synthesis of P_1 ' constrained oxacyclic variants⁹ of the hydroxyethylene isostere present in the Tang–Ghosh pseudo-octapeptide OM99-2.³

Molecular modeling suggested that such a P_1' constrained oxacycle bridging the *C*-methyl group with the

(5) For selected reviews, see: (a) Conway, K. A.; Baxter, E. W.;
Felsenstein, K. M.; Reitz, A. B. Curr. Pharm. Des. 2003, 9, 427. (b)
Ghosh, A.; Hong, L.; Tang, J. Curr. Med. Chem. 2002, 9, 1135. (c)
Roggo, S. Curr. Top. Med. Chem. 2002, 2, 359. (d) Schimmöller, F.;
Higaki, J. N.; Cordell, B. Curr. Pharm. Des. 2002, 8, 2521. (e) Jacobsen,
J. S. Curr. Top. Med. Chem. 2002, 2, 243. (f) Cash, A. D.; Perry, G.;
Smith, M. A. Curr. Med. Chem. 2002, 9, 1605. (g) LeVine, H. Curr.
Med. Chem. 2002, 9, 1121. (h) Wolfe, M. S. J. Med. Chem. 2001, 44, 2039.


(6) (a)Turner, R. T.; Koelsch, G.; Hong, L.; Castaheira, P.; Ghosh,
A. K.; Tang, J. Biochemistry 2001, 40, 10001. (b) Ghosh, A. K.; Shin,
D, Downs, D.; Koelsch, G.; Lin, X.; Ermolieff, J.; Tang, J. J. Am. Chem.
Soc. 2000, 122, 3522. (c) Ghosh, A. K.; Bilcer, G.; Harewood, C.;
Kawahama, R.; Shin, D.; Hussain, K. A.; Hong, L.; Loy, J. A.; Nguyen,
C.; Koelsch, G.; Ermolieff, J.; Tang, J. J. Med. Chem. 2001, 44, 2865.
(7) (a) Coburn, C. A.; Stachel, S. J.; Li, Y.-M.; Rush, D. M.; Steele,

(7) (a) Coburn, C. A.; Stachel, S. J.; Li, Y.-M.; Rush, D. M.; Steele, T. G.; Chen-Dodson, E.; Holloway, M. K.; Xu, M.; Hoang, Q.; Lai, M.-T.; DiMuzio, J.; Crouthamel, M.-C.; Shi, X.-P.; Sardana, V.; Chen, Z.; Munshi, S.; Kuo, L.; Makara, G. M.; Annis, D. A.; Takikonda, P. K.; Nash, H. M.; Vacca, J. P.; Wang, T. J. Med. Chem. 2004, 47, 6117. (b) Kimura, T.; Shuto, D.; Hamada, Y.; Igawa, N.; Kasai, S.; Liu, P.; Hidaka, K.; Hamada, T.; Hayashi, Y.; Kiso, Y. Bioorg. Med. Chem. Lett. 2004, 14, 1527. (c) Hom, R. K.; Gailunas, A. F.; Mamo, S.; Fang, L. Y.; Tung, J. S.; Walker, D. E.; Davis, D.; Thorsett, E. D.; Jewett, N.; Moon, J. B.; John, V. J. Med. Chem. 2004, 47, 158–164. (d) Chen, S.-H.; Lamar, J.; Guo, D.; Kohn, T.; Yang, H.-C.; McGee, J. E.; Timm, D.; Erickson, J. A.; Yip, Y.; May, P.; McCarthy, J. R. Bioorg. Med. Chem. Lett. 2004, 14, 245. (e) Lamar, J.; Hu, J.; Bueno, A. B.; Yang, H.-C.; Guo, D.; Kocarthy, J. R.; Chem, S.-H. Bioorg. Med. Chem. Lett. 2003, 13, 4335. (f) Shuto, D.; Kasai, S.; Kimura, T.; Liu, P.; Hidaka, K.; Hamada, T.; Shibakawa, S.; Hayashi, Y.; Hattori, C.; Szabo, B.; Ishiura, S.; Kiso, Y. Bioorg, Med. Chem. Lett. 2003, 13, 4273. (g) Jeon, S.-Y.; Back, K.; Seong, Y.-H.; Song, K.-S. Bioorg. Med. Chem. Lett. 2003, 13, 3905. (h) Hom, R. K.; Fang, L. Y.; Mamo, S.; Tung, J. S.; Guinn, A. C.; Walker, D. E.; Davis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jawis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jawis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jawis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jawis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jawis, D. L.; Anderson, J. P.; Walker, D. E.; Mamo, S.; Jewett, N.; Hom, R. K.; Sinha, S.; Thorsett, E. D.; John, V. J. Med. Chem. 2003, 46, 1799. (i) Tung, T. S.; Davis, D. L.; Anderson, J. P.; Walker, D. E.; Mamo, S.; Jewett, N.; Hom, R. K.; Sinha, S.; Thorsett, E. D.; John, V. J. Med. Chem. 2003, 45, 1799. (i) Tung, T. S.;

(8) See, for example: (a) Thrombin: Hanessian, S.; Balaux, E.; Nilsson, I. Bioorg. Med. Chem. Lett. **2000**, 10, 243. (b) Factor VIIa: Hanessian, S.; Therrien, E.; Granberg, K.; Nilsson, I. Bioorg. Med. Chem. Lett. **2002**, 12, 2907. (c) Metalloproteases: Hanessian, S.; Moitessier, N.; Gauchet, C.; Viau, M. J. Med. Chem. **2001**, 44, 3064. (d) Hanessian, S.; Mackay, D. B.; Moitessier, N. J. Med. Chem. **2001**, 44, 3074. (e) Neuraminidase: Hanessian, S.; Bayrakdarian, M.; Luo, X. J. Am. Chem. Soc. **2002**, 124, 4716. (f) Hanessian, S.; Wang, J.; Montgomery, D.; Stoll, V.; Stewart, K. D.; Kati, W.; Maring, C.; Kempf, D.; Hutchins, C.; Laver, W. G. Bioorg. Med. Chem. Lett. **2002**, 12, 3425. (g) Renin: Hanessian, S.; Claridge, S.; Johnstone, S. J. Org. Chem. **2002**, 67, 4261.

(9) For another example of the incorporation of a tetrahydrofuranyl unit as a constrain element, see: Hanessian, S.; Moitessier, N.; Wilmouth, S. *Tetrahedron* **2000**, *56*, 7643.

TABLE 1. Stereoselective Aldol Additions



^a Ratios of isomers determined from HPLC analysis. ^b Ratios of isomers determined from isolated weights of individual products.

adjacent methylene carbon shown as a stereochemically defined structure in Figure 1 would not unduly affect the conformation of OM99-2 seen in the X-ray structure. On the basis of this premise, we set out to study methods for the stereoselective synthesis of a 2,3-trans-substituted tetrahydrofuranyl δ -amino acid motif as an integral part of a truncated version of OM99-2 (Figure 1).

Results and Discussion

Our initial studies focused on the aldol condensation of a series of aldehydes readily prepared from N,Ndibenzyl L-amino acids¹⁰ with the lithium enolate of γ -butyrolactone 2.^{11,12} As seen in Table 1, the major products derived from N,N-dibenzyl derivatives of Lleucinal 1a, L-alaninal 1b, and L-phenylalaninal 1c were the corresponding *anti/anti*-aldol 3-furanone products 3a-c, obtained in excellent to good yields. Only minor amounts of the diastereomers 4a and 5a were formed (Table 1, entry 1). Minor quantities of the other diastereomers 4b,c, 5b,c, and 6b,c were formed in the case of 1b and 1c, respectively. (Table 1, entries 2 and 3). The relative stereochemistry of several aldol products was confirmed by single-crystal X-ray analysis.

With the *N*-Boc L-leucinal **1d**, equal amounts of the adducts **3d** and **4d** with only a minor amount of **5d** were isolated. The desired 3-furanone derivative **6d** was not formed under the lithium enolate conditions described above. The relative stereochemistry of the adduct **3d** was determined by transformation to the corresponding pyrrolidinone **7** and correlated with **3a** of known configuration (X-ray) as shown in Scheme 1.

We next explored the Mukaiyama aldol reaction¹³ of the same aldehydes with the trimethylsilyl enol ether of

⁽⁴⁾ For recent reviews, see: (a) Vassar, R. J. Mol. Neurosci. 2004, 23, 105. (b) Bullock, R. Expert Opin. Invest. Drugs 2004, 13, 303. (c) Citron, M. Nat. Rev. Neurosci. 2004, 5, 677. (d) Cumming, J. N.; Iserloh, U.; Kennedy, M. E. Curr. Opin. Drug Discovery Dev. 2004, 7, 536. (e) John, V.; Beck, J. P.; Bienkowski, M. J.; Sinha, S.; Heinrikson, R. L. J. Med. Chem. 2003, 46, 4626. (f) Selkoe, D. J.; Schenk, D. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 545. (g) Golde, T. E. Curr. Pharm. Des. 2003, 9, 427.

^{(10) (}a) Reetz, M. T.; Drewes, M. W.; Schmitz, A. Angew. Chem., Int. Ed. Engl. 1997, 26, 1141. (b) Reetz, M. T. Pure Appl. Chem. 1988, 60, 160. (c) Reetz, M. T. Angew. Chem., Int. Ed. Engl. 1984, 23, 556.
(11) See, for example: (a) Widdowson, D. A.; Wiebecke, G. H.;

⁽¹¹⁾ See, for example: (a) Widdowson, D. A.; Wiebecke, G. H.; William, D. J. *Tetrahedron* **1982**, 23, 4285. For review, see: (b) Evans, D. A.; Nelson, J. V.; Taber, T. R. *Top. Stereochem.* **1982**, *131*. (c) Heathcock, C. H. *Science* **1981**, 214, 395. (d) Heathcock, C. H. *Comprehensive Carbanion Chemistry*; Buncel, E., Durst, T., Eds.; Elsevier: Amsterdam, 1984; Vol. 2.

⁽¹²⁾ For a review on γ -butyrolactones, see: Canan Kosh, S. S.; Chamberlin, A. R. In *Stereoselective Synthesis, Part J*; Rahman, A.-U., Ed.; Studies in Natural Products Chemistry; Elsevier: New York, 1995; Vol. 16, p 687.

SCHEME 1





 TABLE 2. Stereoselective Mukaiyama Aldol Additions

			H 8 , LA		Ļ	
		1a-d				
Entry	R	Lewis acid	NBn ₂ 3a-c	R NBn ₂ 4a-c	R NBn ₂ 5a-c	R NBn ₂ 6a-c
1 a	<i>i</i> -Pr, 1a	EtAlCl2 ^c	10	0	90	0
2 ^{<i>a</i>}	<i>i</i> -Pr, 1a	BF ₃ etherate ^c	0	0	91	9
3 ^a	<i>i</i> -Pr, 1a	$ZnBr_2$ ^c	3	0	91	6
4 ^{<i>a</i>}	<i>i</i> -Pr, 1a	$MgBr_2^{\ d}$	0	0	78	22
5 ^a	<i>i</i> -Pr, 1a	YbFOD^d	0	23	45	32
6 ^{<i>a</i>}	<i>i</i> -Pr, 1a	Cu(OTf)2 ^d	0	0	21	79
7 ^a	H, 1b	YbFOD ^d	14	11	63 (X-ray)	12
8 ^a	H, 1b	$Cu(OTf)_2^d$	5	10	8	77 (X-ray)
9 ^a	Ph, 1c	YbFOD ^d	2	27	42	29
10 ^a	Ph, 1c	Cu(OTf)2 ^d	0	14 (X-ray)	8	78 (X-ray)
			R HBoc		R NHBoc 5d	R NHBoc 6d
11 ^b	<i>i</i> -Pr, 1d	YbFOD ^d	0	7	0	93

^{*a*} Ratios of isomers determined from HPLC analysis. ^{*b*} Ratios of isomers determined from isolated weights of individual products. ^{*c*} The reaction was done at -78 °C. ^{*d*} The reaction was done at room temperature with a catalytic quantity (5 mol %) of reagent.

 γ -butyrolactone **8** in the presence of a variety of Lewis acids in stoichiometric or catalytic quantities.¹⁴ The distribution of diastereometric adducts was drastically changed compared to that of the lithium enolates, as seen in Table 2. Thus, with EtAlCl₂, BF₃·Et₂O, MgBr₂, and ZnBr₂, the *syn/anti*-aldol product **5a** was the major isomer (Table 2, entries 1–4). A reversal in favor of the desired *syn/syn*-aldol **6a** was observed with Cu(OTf)₂ (Table 2, entry 6). This trend was also evident in the case of **1b** (Table 2, entry 8) and **1c** (Table 2, entry 10). Using catalytic quantities of YbFOD¹⁵ diminished the diastereoselectivity with all three aldehydes to give mixtures



of the anti/syn-, syn/anti-, and syn/syn-isomers $4\mathbf{a}-\mathbf{c}$, $5\mathbf{a}-\mathbf{c}$, and $6\mathbf{a}-\mathbf{c}$, respectively, in good yields. On the other hand, YbFOD was the preferred catalyst for the synthesis of the desired isomer $6\mathbf{d}$ in the case of the N-Boc L-leucinal.

We observed an interesting interconversion of diastereomers in our attempts to convert the isomeric $3\mathbf{a}-\mathbf{c}$ adducts into the corresponding O-TBS ethers (Scheme 2). Thus, treatment of **3a** (or **5a**) with TBS triflate in the presence of 2,6-lutidine afforded the *syn/anti*-isomer **9** in 96% yield (X-ray). Similarly, treatment of 4a (or 6a) under the same conditions gave the syn/syn-isomer 10 in 95% yield. In each case, complete epimerization at the furanone (C-3) branching site had taken place with isomers 3a and 4a. This can be rationalized on the basis of initial formation of a TBS silyl ether, followed by enolate formation and concomitant participation of the enolate hydroxyl group to give a transient hypervalent dioxasilicon intermediate.¹⁶ Protonation from the least hindered face affords the respective products 9 and 10, as illustrated in the perspective drawings A and B (Scheme 2). The same trend was observed in the case of the TBS ethers of **3b** and **3c**, which were converted to the diastereoimeric TBS ethers **5b** and **5c**, respectively. Similarly, **4b** and **4c** afforded **6b** and **6c** (as TBS ethers).

The stereoselective formation of the major products $3\mathbf{a}-\mathbf{c}$ in the Li enolate aldol reaction with the *N*,*N*-dibenzyl aldehydes $1\mathbf{a}-\mathbf{c}$ can be explained on the basis of a preferred *Re*-face attack by the enolate in a Zimmerman-Traxler-type transition state (Figure 2A). The observed *anti/anti*-aldol products $3\mathbf{a}-\mathbf{c}$ (Table 1, entries 1-3) may be explained by considering a Felkin-Anh model with a "pseudoequatorial" orientation of the large *N*,*N*-dibenzylamino group in A (as compared to a *Si*-face

^{(13) (}a) Mukaiyama, T. Org. React. 1982, 28, 203. (b) Mukaiyama,
T.; Banno, K.; Narasaka, K. J. Am. Chem. Soc. 1974, 96, 7503.
(14) See, for example: (a) Heathcock, C. H.; Davidsen, S. K.; Hug,

⁽¹⁴⁾ See, for example: (a) Heathcock, C. H.; Davidsen, S. K.; Hug, K. T.; Flippin, L. A. J. Org. Chem. **1986**, *51*, 3027. (b) Chen, C.-T.; Chao, S.-D.; Yen, C.-C. Synlett **1998**, 924. For a catalytic version, see: (c) Evans, D. A.; Kozlowski, M. C.; Murry, J. A.; Burgey, C. S.; Campos, W. P. G. C., C. S. (c) L. L. C. (c) Composed and the set of the

^{K. R.; Connell, B.-T.; Staples, R. J. J. Am. Chem. Soc. 1999, 121, 669. (15) For reviews, see: (a) Kobayashi, S. Synlett 1994, 689. (b) Molander, G. A. Chem. Rev. 1992, 92, 29. (c) Collin, J.; Giuseppone, N.; van de Weghe, P. Coord. Chem. Rev. 1998, 178–180, 117. See also: (d) Midland, M. M.; Koops, R. W. J. Org. Chem. 1990, 55, 4647. (e) Gong, L.; Streitweiser, A. J. Org. Chem. 1990, 55, 6235.}

⁽¹⁶⁾ Mulzer, J.; Schollhorn, B. Angew. Chem., Int. Ed. 1990, 29, 431.




FIGURE 2. Possible transition state models for aldol additions.

attack B). The nature of the side chain does not have a significant stereodirecting influence, since the major isomer is the *anti/anti*-aldol product from 1a-c, albeit with some differences in the case of phenyl analogue 1c. The equal amounts of diastereomers 3d and 4d in the case of the *N*-Boc-protected aldehydes (Table 1, entry 4) may be due to loss of stereodifferentiation caused by internally chelated intermediates involving the *N*-Boc group. The same trend has been observed in related cases by Reetz and co-workers.¹⁷

The Mukaiyama aldol product favoring the syn/antiand *syn/syn*-aldol isomers **5a**–**c** or **6a**–**c** can be rationalized based on whether nonchelated or chelated transition states are involved, respectively.^{14,15} Thus, with the N,Ndibenzyl aldehydes 1a-c and monodentate Lewis acids such as EtAlCl₂ and BF₃ etherate, the major product **5a** can arise from nonchelated intermediate A (Figure 3). The bidentate MgBr₂ gave a ca. 3:1 ratio of **5a** and **6a**, reflecting a contribution from the chelated transition state, leading to intermediate B (Figure 3, Table 2, entry 4). Curiously, $ZnBr_2$ led to a preponderance of **5a**, although a chelated transition state may be expected (Figure 3, Table 2, entry 3).^{10c} In the presence of Cu(OTf)₂, the syn-aldol isomer 6a was formed, regardless of the nature of the aldehyde, presumably arising from a chelated transition state (Table 2, entries 6, 8, and 10).

Using catalytic quantities of the lanthanide YbFOD led to mixtures of $4\mathbf{a}-\mathbf{c}$, $5\mathbf{a}-\mathbf{c}$, and $6\mathbf{a}-\mathbf{c}$ (Table 2, entries 5, 7, and 9). The nature of the side chain seems not to have a significant effect on the ratio of isomers, although a preference for **5b** was observed compared to the larger aldehyde precursors (Table 2, entries 5, 7, and 9). On the other hand, catalytic YbFOD led to an excellent stereoselectivity in favor of the desired *syn/syn*-aldol isomer **6d** in the case of the *N*-Boc L-leucinal **1d**, presumably arising from a kinetically controlled addition proceeding via B (Figure 3).




FIGURE 3. Possible chelated and nonchelated transition state models for Mukaiyama aldol condensations.


From a practical standpoint, we were pleased that, depending on the type of catalyst or method used, each of the four possible diastereomers of the adducts 3-6could be obtained in preparatively significant amounts. More rewarding, however, was the success of the Mukaiyama aldol reaction in the presence of a catalytic quantity of YbFOD to furnish the desired *syn/syn-N*-Boc lactone **6d** in high yield.

For the purposes of obtaining the intended P_1' constrained motif (Figure 1), we opted to proceed with the syn/syn-N,N-dibenzyl lactone 10, obtained from 6a and 4a via TBS ether formation in excellent overall yield. Treatment of 10 with lithio dithiane¹⁸ at -78 °C led to a mixture of ketone 11a and the hemiacetals 11b,c (Scheme 3). Reduction of this mixture with NaBH₄ gave essentially a single isomer 12. Intramolecular cycloetherification under Mitsunobu¹⁹ conditions led to 13 in 87% yield, whose structure and absolute configuration were ascertained from a single-crystal X-ray analysis. It follows that the reduction of the ketone with NaBH₄ had given the 2S-alcohol stereoselectively and that the cycloetherification had proceeded without inversion of configuration, as would be expected from the activation of a primary alcohol. An alternative route involving cycloetherification by tosylation of the primary alcohol in 12 and intramolecular displacement gave 13 in only 50% yield even after 24 h. Treatment of 13 with HgCl₂/CaCO₃ or CH₃I/ Na₂CO₃ did not give the desired aldehyde. However, a mixture of HgO and BF₃ etherate²⁰ cleaved the dithianyl

⁽¹⁷⁾ Reetz, M. T. Chem. Rev. 1999, 99, 1121.

⁽¹⁸⁾ Sanchez, M. E. L.; Michelet, V.; Besnier, I.; Genet, J. P. Synlett 1994, 705.


^{(19) (}a) Mitsunobu, O. Synthesis **1981**, 1. (b) Hughes, D. L. Org. React. **1992**, 42, 335. (c) Hanessian, S.; Machaalani, R. Tetrahedron Lett. **2003**, 44, 8321. (d) Hanessian, S.; Marcotte, S.; Machaalani, R.; Huang, G. Org. Lett. **2003**, 5, 4273. (e) Guianvac, H.; Fourrey, J.-L.; Tram Huu Dan, M.-E.; Guerineau, V.; Benhid, R. J. Org. Chem. **2002**, 67, 3724.



^a Reagents and conditions: (a) 1,3-Dithiane, *n*-BuLi, THF, -78 to 0 °C; (b) NaBH₄, MeOH, room temperature, 58%, two steps; (c) PPh₃, DEAD, THF, room temperature, 87%; (d) TsCl, pyridine, 0 °C to room temperature 50%; (e) HgO, BF₃ etherate, CH₃CN/H₂O, room temperature, 84%; (f) (i) NaOCl₂, 2-methyl-2-butene, buffer, CH₃CN/H₂O, room temperature, 52%; (ii) CH₂N₂; (g) NaOMe/ MeOH, reflux; (h) NaOH, MeOH/H₂O, 80% for two steps.

group and produced 14 in high yield. Oxidation to the acid with NaClO₂,²¹ and esterification with CH_2N_2 gave 15, which was epimerized to 16 with NaOMe and MeOH. The desired acid 17 was obtained by alkaline hydrolysis and separated from the minor unepimerized isomer by column chromatography. An alternative synthesis of a precursor to 16 using nitroaldol methodology under Shibasaki catalytic conditions²² was recently reported by us.²³

With a preparative route to the P_1/P_1' constrained tetrahydrofuran amino acid 17 in hand, we proceeded to prepare three prototypical truncated mimics of OM99-2. Extensive SAR studies on OM99-2 in conjunction with X-ray crystallography of complexes with BACE1 have shown that certain amino acid components of the heptapeptide can be changed without significant loss of activity.^{6c} For example, the P2'-P4' units can be truncated and replaced by a simple alkylamide chain. The Asp subunit has also been changed to Met in an effort to decrease the polar nature of the inhibitor. We therefore adapted these changes to our constrained oxacyclic variant of OM99-2 to ultimately have three prototypical and diversely substituted mimics. Thus, the free acid **17** was coupled with *n*-butylamine, with L-Ala methylamide, SCHEME 4^a



21a, $R_1 = n$ -butyl, $R_2 = CH_2CONH_2$, $R_3 = i$ -Pr **21b**, $R_1 = Ala$ -methylamide, $R_2 = CH_2CONH_2$, $R_3 = i$ -Pr **21c**, $R_1 = Val$ -n-butylamide, $R_2 = CH_2CH_2SCH_3$, $R_3 = 2$ -methyl-butyl

^a Reagents and conditions: (a) *n*-Butylamine or L-Ala-methylamide or L-Val-*n*-butylamide, PyBop, *i*-Pr₂NEt, DCM, 0 °C to room temperature; (b) (i) Pd-black, HCOOH/MeOH; (ii) Boc₂O, NaHCO₃, MeOH; (iii) TBAF; (c) (i) HCl in dioxane (4 M); (ii) N'-Tr-L-AspOH or N-Boc-MetOH, PyBOP, DIEA, DCM, 0 °C to room temperature; (d) Ac-L-ValOH or Ac-L-LeuOH, HOBT, EDC, DCM/H₂O, 0 to 5 °C; for **20a,b**, TFA/H₂O, room temperature.

and L-Val *n*-butylamide to give **18a**-c, respectively (Scheme 4). Catalytic transfer hydrogenation removed the N,N-dibenzyl group, and the resulting amine was protected as the N-Boc derivative before treatment with TBAF to cleave the silvl ether group, to afford 19a-c in excellent overall yield. Removal of the N-Boc group and coupling with N'-Tr-BocAspOH, mediated by PyBop, afforded 20a and 20b. In the case of 19c, coupling was done with BocMetOH to give 20c. Further extension of 20a and 20b with AcValOH, followed by acid treatment, gave the pseudopeptides 21a and 21b, respectively (Scheme 4). Similarly, extension of 20c with AcLeuOH gave **21c**, thus completing the intended series of oxacyclic analogues of OM99-2. To avoid epimerization, we found EDC/HOBT in a two-phase system (CH_2Cl_2/H_2O) to be advantageous in the preparation of 21a-c.

Compounds **21a**–**c** were tested for their ability to inhibit BACE1. Weak inhibitory activity was observed only with **21c** (IC₅₀ = 8.5 μ M).²⁴ Although **21a** was inactive against BACE1, it showed inhibition against pepsin and cathepsin D with IC₅₀ values of 0.17 and 0.28 μ M, respectively. Compound **21b** was devoid of activity with all three enzymes. The carbocyclic analogue of **21c** in which the tetrahydrofuran ring is replaced by a cyclopentane and a cyclopentanone are low nanomolar inhibitors of BACE1.²⁴ The substantial loss of activity

⁽²⁰⁾ Vedejs, E.; Fuchs, P. L. J. Org. Chem. 1971, 36, 366.

^{(21) (}a) Bal, B. S.; Childers, W. E.; Pinnick, H. W. Tetrahedron **1981**, 37, 2091. (b) Kraus, G. A.; Tashner, M. J. J. Org. Chem. **1980**, 45, 1175.

 ⁽c) Lindgren, B. O.; Nilsson, T. Acta Chem. Scand. 1973, 27, 888.
 (22) (a) Sasai, H.; Suzuki, T.; Arai, S.; Shibasaki, M. J. Am. Chem.

Soc. 1991, 111, 4418. (b) Shibasaki, M.; Yoshikawa, N. Chem. Rev. 2002, 102, 2187.

⁽²³⁾ Hanessian, S.; Brassard, M. Tetrahedron 2004, 60, 7621.

⁽²⁴⁾ Hanessian, S.; Yun, H.; Hou, Y.; Yang, G.; Bayrakdarian, M.; Therrien, E.; Moitessier, N.; Roggo, S.; Veenstra, S.; Tintelnot-Blomley, M.; Rondeau, J.-M.; Paganetti, P.; Betschart, C. J. Med. Chem., published online July 15, 2005. http://dx.doi.org/10.1021/jm050142+.

when a cyclopentane is replaced by an oxacyclic analogue might be the result of repulsive interactions of the ring oxygen atom with amide carbonyls in the active site, thus deviating from optimal conformations for binding. Further studies aimed at the modification of the acyclic backbone with azacyclic constrained isosteres OM99-2 are reported in the companion article.²⁵

Experimental Section

(3S)-3-[(1R,2S)-2-Dibenzylamino-1-hydroxy-4-methylpentyl]-dihydro-furan-2-one (3a). Method A, LiHMDS: To a dry flask containing LiHMDS (1.4 mL, 1.0 M in THF) was added THF (5 mL), and the solution was cooled to -78 °C. γ -Butyrolactone (100 μ L, 1.30 mmol) was added dropwise, and the reaction mixture was stirred for 0.5 h. A cold solution of 1a (265 mg, 0.90 mmol) in THF (10 mL) was added dropwise by cannula, and the reaction mixture was stirred for a further 2 h at -78 °C before quenching with saturated aqueous NH₄-Cl (10 mL). The reaction mixture was extracted with EtOAc $(15 \text{ mL} \times 3)$, and the organic phase was dried with Na₂SO₄ and concentrated. The residue was purified by column chromatography (20% EtOAc in hexanes) to afford ${\bf 3a}$ (252 mg, 66%) as a white solid; mp 114-115 °C; [α]_D -27.5 (c 1.1, CHCl₃); ¹H NMR (CDCl₃) δ 0.55 (3H, d, J = 6.4 Hz), 0.96 (3H, d, J = 6.7 Hz), 1.04 (1H, m), 1.90 (2H, m), 2.02 (2H, m), 2.00 (1H, m), 2.58 (2H, m), 3.55 (2H, d, J = 14.0 Hz), 4.02 (2H, d, J = 14.0 Hz), 4.08 (1H, s), 4.12 (1H, m), 4.28 (1H, d, J = 9.5Hz), 4.34 (1H, m), 7.31 (10 H, m); ¹³C NMR (CDCl₃) δ 22.1, 24.5, 24.6, 26.1, 34.5, 42.9, 54.9, 56.4, 67.1, 70.4, 127.3, 128.6, 129.3, 141.1, 181.0; IR (film) 3499, 3028, 2953, 1753; MS (FAB) m/z 382 [M + 1]⁺; HRMS calcd for C₂₄H₃₂NO₃ [M + 1]⁺ 382.2382; found 382.2373.

(3S)-3-[(1*R*,2S)-2-Dibenzylamino-1-hydroxy-propyl]-dihydro-furan-2-one (3b). The compound was prepared from 1b as described above (Method A, LiHMDS). Purification by column chromatography (20% EtOAc in hexanes) gave 3b as a colorless oil (52%); [a]_D +28.3 (*c* 0.4, CHCl₃); ¹H NMR (CDCl₃) δ 1.18 (3H, d, J = 6.8 Hz), 1.72 (1H, m), 1.88 (1H, m), 2.75 (1H, m), 2.90 (1H, m), 3.60 (2H, d, J = 13.8 Hz), 3.82 (1H, s), 3.84 (2H, d, J = 13.8 Hz), 3.90 (1H, dd, J = 7.2 and 4.5 Hz), 4.07 (1H, m), 4.27 (1H, td, J = 8.8 and 1.5 Hz), 7.20–7.37 (10 H, m); ¹³C NMR (CDCl₃): δ 8.3, 26.3, 42.5, 55.1, 55.3, 67.1, 74.5, 127.3, 128.6, 128.9, 129.2, 140.8, 179.8; IR (film) 3495, 3027, 2934, 1754; MS (FAB) *m*/*z* [M + 1]+; HRMS calcd for C₂₁H₂₆NO₃ [M + 1]+ 340.1912; found 340.1872.

(3*R*)-3-[(1*S*,2*S*)-2-Dibenzylamino-1-hydroxy-propyl]-dihydro-furan-2-one (4b). The compound was isolated as the second isomer in the preparation of **3b**. Purification by column chromatography (20% EtOAc in hexanes) gave **4b** as a colorless oil (19%); [α]_D +18.8 (*c* 0.3, CHCl₃); ¹H NMR (CDCl₃) δ 1.15 (3H, d, *J* = 6.7), 2.05 (2H, m), 2.73 (1H, td, *J* = 8.3 and 3.6 Hz), 3.24 (1H, m), 3.36 (2H, d, *J* = 13.2 Hz), 3.66 (1H, dd, *J* = 8.2 and 3.6 Hz), 3.86 (2H, d, *J* = 13.2 Hz), 4.13 (1H, dd, *J* = 15.7 and 7.2 Hz), 4.31 (1H, dd, *J* = 15.5 and 7.2 Hz), 4.58 (1H, br), 7.23-7.33 (10 H, m); ¹³C NMR (CDCl₃) δ 9.1, 26.9, 41.3, 54.2, 54.9, 67.7, 74.1, 127.7, 128.9, 129.6, 139.4, 178.1; R (film) 3500, 3028, 2918, 1766; MS (EI) *m*/*z* 339.1 [M + 1]⁺; HRMS calcd for C₂₁H₂₅NO₃ [M + 1]⁺ 339.1834; found 339.1834.

(3S)-3-[(1*R*,2S)-2-Dibenzylamino-1-hydroxy-3-phenylpropyl]-dihydro-furan-2-one (3c). The compound was prepared from 1c as described above (Method A, LiHMDS). Purification by column chromatography (20% EtOAc in hexanes) gave 3c as a colorless oil (46%); [α]_D +23.2 (*c* 0.5, CHCl₃); ¹H NMR (CDCl₃) δ 1.50 (2H, m), 2.24 (1H, m), 2.92 (1H, m), 3.08 (2H, m), 3.83 (4H, s), 3.89 (1H, m), 4.13 (1H, s), 4.20 (1H, d, *J* = 9.04), 4.62 (1H, m), 7.15-7.28 (15 H, m); ¹³C NMR (CDCl₃) δ 26.0, 30.9, 43.2, 55.1, 61.0, 67.0, 73.5, 126.5, 127.2, 128.6, 128.7, 129.0, 130.0, 140.7, 141.0, 180.6; IR (film) 3506, 3062, 3026, 2916, 1751; MS (FAB) m/z 416.2 [M + 1]+; HRMS calcd for $C_{27}H_{29}NO_3$ [M + 1]+ 416.2225; found 416.2216.

(3*R*)-3-[(1*S*,2*S*)-2-Dibenzylamino-1-hydroxy-3-phenylpropyl]-dihydro-furan-2-one (4c). The compound was isolated as the second isomer in the preparation of 3c. Purification by column chromatography (20% EtOAc in hexanes) gave 4c as a colorless oil (10%); mp 147–148 °C; $[\alpha]_D$ +18.2 (*c* 0.4, CHCl₃); ¹H NMR (CDCl₃) δ 1.07 (1H, m), 1.59 (2H, m), 2.14 (1H, m), 2.59 (1H, dd, J = 14.3 and 8.8 Hz), 2.85 (1H, m), 3.28 (1H, dd, J = 14.2 and 3.9 Hz), 3.42 (2H, d, J = 13.0 Hz), 3.80 (1H, m), 4.04 (3H, m), 4.24 (1H, dd, J = 8.95 and 1.6 Hz), 4.71 (1H, s), 7.13–7.39 (15 H, m); ¹³C NMR (CDCl₃) δ 20.9, 32.3, 43.1, 53.9, 62.0, 67.5, 69.5, 127.1, 128.0, 129.1, 129.3, 129.3, 129.6, 138.6, 139.9, 178.8; IR (film) 1770; MS (FAB) *m/z* 416.2 [M + 1]⁺; HRMS calcd for C₂₇H₂₉NO₃ [M + 1]⁺ 416.2225; found 416.2223.

(3S)-3-[(1R,2S)-2-*tert*-Butoxycarbonylamino-1-hydroxy-4-methyl-pentyl]-dihydro-furan-2-one (3d). The compound was prepared from 1d as described above (Method A, LiH-MDS). Purification by column chromatography (30% EtOAc in hexanes) gave 3d as a colorless oil (24%); $[\alpha]_D - 24.1 (c \ 0.3,$ CHCl₃); ¹H NMR (CDCl₃) δ 0.92 (3H, d, J = 6.6 Hz), 0.94 (3H, d, J = 6.7 Hz), 1.13 (1H, m), 1.43 (9H, s), 1.54 (1H, m), 1.69 (1H, m), 2.28 (2H, m), 2.49 (1H, m), 2.60 (1H, m), 3.67 (1H, t, J = 9.6 Hz), 3.85 (1H, m), 4.24 (1H, m), 4.35 (1H, t, J = 7.0Hz), 4.43 (1H, t, J = 8.8 Hz), 4.95 (1H, d, J = 9.4 Hz); ¹³C NMR (CDCl₃) δ 180.4, 156.3, 79.8, 74.8, 67.6, 50.9, 42.2, 37.3, 28.8, 25.6, 24.9, 24.3, 21.9; IR (film) 3391, 2958, 2871, 1759, 1698, 1512; MS (FAB) *m*/*z* 302.1 [M + 1]⁺; HRMS calcd for C₁₅H₂₈NO₅ [M + 1]⁺ 302.1967; found 302.1954.

(3*R*)-3-[(1*S*,2*S*)-2-*tert*-Butoxycarbonylamino-1-hydroxy-4-methyl-pentyl]-dihydro-furan-2-one (4d). The compound was isolated as the second isomer in the preparation of **3d**. Purification by column chromatography (30% EtOAc in hexanes) gave **4d** as a colorless oil (27%); [α]_D -37.3 (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.93 (3H, d, *J* = 2.6 Hz), 0.94 (3H, d, *J* = 2.6 Hz), 1.34 (1H, m), 1.44 (9H, s), 1.64 (2H, m), 1.98 (1H, m), 2.61 (1H, m), 2.64 (1H, m), 3.68 (2H, m), 4.24 (1H, m), 4.43 (2H, m), 4.79 (1H, d, *J* = 10.2 Hz); ¹³C NMR (CDCl₃) δ 22.71, 23.3, 25.2, 26.3, 28.7, 42.1, 50.4, 67.7, 74.2, 79.7, 81.6, 156.5; IR (film) 3453, 3360, 2960, 2871, 1755, 1707, 1503, 1455; MS (EI) *m*/*z* 301.2 [M]⁺; HRMS calcd for C₁₅H₂₇NO₅ [M]⁺ 301.1889; found 301.1901.

(3*R*)-3-[(1*R*,2*S*)-2-*tert*-Butoxycarbonylamino-1-hydroxy-4-methyl-pentyl]-dihydro-furan-2-one (5d). The compound was isolated as the third isomer in the preparation of 3d. Purification by column chromatography (30% EtOAc in hexanes) gave 5d as a white solid (4%); [α]_D – 4.2 (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.95 (3H, d, J = 6.5 Hz), 0.98 (3H, d, J = 6.6 Hz), 1.27 (1H, m), 1.45 (9H, s), 1.60 (1H, m), 1.71 (1H, m), 2.40 (1H, m), 2.50 (1H, m), 2.81 (1H, m), 3.74 (1H, m), 3.99 (1H, dd, J = 7.4 and 2.2 Hz), 4.22 (1H, dd, J = 16.4 and 9.1 Hz), 4.38 (1H, m), 4.41 (1H, m); ¹³C NMR (CDCl₃) δ 21.9, 22.7, 24.1, 25.2, 28.7, 41.1, 43.3, 52.3, 67.8, 73.6, 80.3, 156.7, 179.8; IR (film) 3354, 2958, 1758, 1607, 1524, 1367; MS (FAB) *m*/*z* 302.2 [M + 1]⁺; HRMS calcd for C₁₅H₂₈NO₅ [M + 1]⁺ 302.1967; found 302.1968.

(3*R*)-3-[(1*R*,2*S*)-2-Dibenzylamino-1-hydroxy-4-methylpentyl]-dihydro-furan-2-one (5a). Method B, EtAlCl₂: To a solution of the aldehyde 1a (162 mg, 0.55 mmol) in CH₂Cl₂ (5 mL) at -78 °C was added EtAlCl₂ (1.0 M in hexanes, 0.55 mL), and the reaction mixture was stirred for 10 min. (4,5-Dihydro-furan-2-yloxy)-trimethylsilane (7) (130 mg, 0.82 mmol) in CH₂Cl₂ (2 mL) was added dropwise, and the reaction mixture was stirred at -78 °C for 2 h, after which it was quenched by adding saturated aqueous NH₄Cl (10 mL), then warmed to room temperature. Extraction with EtOAc (15 mL × 3) and concentration gave an oil that was redissolved in THF (10 mL), aqueous HCl (1%, 1.0 mL) was added, and the solution was stirred for 30 min before it was neutralized with saturated NaHCO₃ and extracted with EtOAc (3 × 10 mL).

⁽²⁵⁾ Hanessian, S.; Yun, H.; Hou, Y.; Tintelnot-Blomley, M. J. Org. Chem. 2005, 70, 6746.

Concentration and purification by column chromatography (20% EtOAc in hexanes) gave **5a** as a colorless oil (162 mg, 78%); $[\alpha]_D + 26.2 (c \ 0.50, CHCl_3)$; ¹H NMR (CDCl₃) $\delta \ 0.84$ (1H, m), 0.98 (6H, m), 1.55 (2H, m), 1.93 (2H, m), 2.40 (1H, m), 2.51 (1H, m), 3.23 (1H, t, J = 9.4), 3.40 (2H, d, J = 13.2 Hz), 3.70 (2H, d, J = 13.2 Hz), 3.90 (1H, dd, J = 8.7 and 16.7 Hz), 4.16 (1H, m), 4.25 (1H, m), 7.30 (10 H, m); ¹³C NMR (CDCl_3) $\delta \ 21.0, 23.3, 24.0, 26.7, 36.7, 44.2, 54.6, 57.2, 67.7, 71.9, 127.5, 128.7, 129.9, 140.4, 181.0; IR (film) 3509, 3028, 2956, 1753. MS (FAB) <math>m/z$ 382 [M + 1]⁺; HRMS calcd for C₂₄H₃₂NO₃ [M + 1]⁺ 382.2382; found 382.2392.

 $(3S) \hbox{-} 3 \hbox{-} [(1S, 2S) \hbox{-} 2 \hbox{-} Dibenzy lamino \hbox{-} 1 \hbox{-} hydroxy \hbox{-} 4 \hbox{-} methyl$ pentyl]-dihydro-furan-2-one (6a). Method C, Cu(OTf)₂: To a solution of the aldehyde 1a (26 mg, 0.087 mmol) in CH₂Cl₂ (1 mL) was added Cu(OTf)₂ (35 mg, 0.087 mmol) at room temperature, and the reaction mixture was stirred for 15 min. (4.5-Dihydro-furan-2-yloxy)-trimethyl-silane (7) (25 mg, 0.174 mmol) was added in one portion, and the reaction mixture was stirred at room temperature until full consumption of the starting aldehyde (5 h). Saturated NaHCO₃ (2 mL) was added, and the reaction mixture was extracted with EtOAc (3 \times 5 mL). The organic phase was concentrated, the residue was redissolved in THF (10 mL), aqueous HCl (1%, 1.0 mL) was added, and the solution was stirred for 30 min before it was neutralized with NaHCO₃, extracted with EtOAc (3 \times 10 mL), dried over Na₂SO₄, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography (20% EtOAc in hexanes) to afford **6a** as a colorless oil (16 mg, 50%); $[\alpha]_{\rm D}$ +0.8 (c 0.5, CHCl₃); ¹H NMR (CDCl₃) δ 0.96 (6H, m), 1.25 (2H, m), 1.68 (3H, m), 2.58 (2H, m), 3.45 (2H, d, J = 13.2 Hz),3.90 (2H, d, J = 13.2 Hz), 4.04 (1H, m), 4.23 (1H, m), 4.71(1H, m), 7.30 (10 H, m); ¹³C NMR (CDCl₃) δ 21.3, 23.4, 23.7, 27.1, 36.3, 42.9, 54.6, 57.8, 67.6, 70.1, 127.9, 129.0, 129.7, 179.1; IR (film) 3400, 2957, 1769, 1453; MS (FAB) m/z [M + 1]+; HRMS calcd for $C_{24}H_{32}NO_3 [M + 1]^+ 382.2382$; found 382.2372.

(3S)-3-[(1S,2S)-2-Dibenzylamino-1-hydroxy-propyl]-dihydro-furan-2-one (6b). The compound was prepared from 1b as described above (Method C, Cu(OTf)₂). Purification by column chromatography (20% EtOAc in hexanes) gave 6b as a white solid (29%); mp 121–122 °C; [α]_D +20.1 (*c* 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 1.08 (3H, d, J = 6.6 Hz), 1.83 (2H, m), 2.54 (2H, m), 3.30 (2H, d, J = 13.1 Hz), 3.86 (2H, d, J = 13.1 Hz), 4.13 (2H, m), 4.22 (1H, m), 4.45 (1H, br), 7.26–7.38 (10 H, m); ¹³C NMR (CDCl₃) δ 8.3, 20.8, 39.7, 42.4, 53.6, 55.8, 67.6, 69.8, 127.9, 129.0, 129.5, 130.2, 138.8, 179.1; IR (film) 3370, 3028, 2968, 1770; MS (EI) *m/z* 339.1 [M + 1]⁺; HRMS calcd for C₂₁H₂₅NO₃ [M + 1]⁺ 339.1834; found 339.184723.

(3R)-3-[(1S,S)-2-Dibenzylamino-1-hydroxy-4-methylpentyl]-dihydro-furan-2-one (4a). Method D, YbFOD: To a solution of aldehyde 1a (2.7 g, 9.11 mmol) in CH₂Cl₂ (100 mL) was added YbFOD (482 mg, 0.46 mmol, 5 mol %). After 5 min, (4,5-dihydro-furan-2-yloxy)-trimethyl-silane (7) (2.88 g, 18.22 mmol) was added in one portion. The reaction mixture was stirred under Ar until full consumption of the starting material (6 h), after which it was quenched with 10 mL of water, and the organic phase was dried with Na₂SO₄ and concentrated under reduced pressure. The residue was redissolved in THF (100 mL), aqueous HCl (1%, 10 mL) was added, and the solution was stirred for 30 min before it was neutralized with saturated NaHCO3, extracted with EtOAc (3 \times 100 mL), and dried with Na₂SO₄. The combined organic phase was concentrated, and the residue was purifed by column chromatography (20% EtOAc in hexanes) to afford 4a as a white crystalline solid (798 mg, 23%); mp 143–144 °C; [α]_D +27.1 (c 0.6, CHCl₃); ¹H NMR (CDCl₃) δ 0.91 (1H, s), 0.95 (3H, d, J =6.4 Hz), 1.05 (3H, d, J = 6.4 Hz), 1.44 (1H, m), 1.55 (1H, m), 1.73 (1H, m), 1.80 (1H, m), 2.65 (1H, m), 3.00 (1H, m), 3.35 (2H, d, J = 13.2 Hz), 3.66 (1H, dd, J = 4.04 and 7.58 Hz), 3.93(1H, m), 4.00 (1H, b), 4.16 (1H, m), 4.67 (1H, s), 7.29 (10 H, m); ¹³C NMR (CDCl₃) δ 22.5, 24.4, 25.9, 26.2, 33.5, 41.2, 55.8, 56.2, 67.4, 74.2, 127.4, 128.6, 129.8, 140.9, 181.1; IR (film) 3469, 3028, 2955, 1748; MS (FAB) m/z 382.2 $[\rm M+1]^+; \rm HRMS$ calcd for $\rm C_{24}H_{32}NO_3~[M+1]^+$ 382.2382; found 382.2362.

(3*R*)-3-[(1*R*,2*S*)-2-Dibenzylamino-1-hydroxy-propyl]-dihydro-furan-2-one (5b). The compound was prepared from 1b as described above (Method D, YbFOD). Purification by column chromatography (20% EtOAc in hexanes) gave 5b as a white solid (55%); mp 158–159 °C; [α]_D +35.9 (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.91 (1H, m), 1.21 (3H, d, *J* = 6.6 Hz), 1.80 (1H, m), 2.21 (1H, m), 2.62 (1H, m), 3.26 (1H, m), 3.30 (2H, d, *J* = 12.8 Hz), 3.71 (2H, d, *J* = 12.8 Hz), 3.96 (1H, dd, *J* = 16.3 and 9.2 Hz), 4.14 (2H, m), 7.26–7.33 (10 H, m); ¹³C NMR (CDCl₃) δ 8.8, 20.6, 43.5, 54.5, 55.0, 67.7, 71.7, 127.6, 128.7, 128.8, 129.2, 129.6, 129.8, 140.1, 180.9; IR (film) 3469, 3028, 2917, 2807, 1753; MS (FAB) *m/z* 340.2 [M + 1]⁺; HRMS calcd for C₂₁H₂₆NO₃ [M + 1]⁺ 340.1912; found 340.1916.

(3*R*)-3-[(1*R*,2*S*)-2-Dibenzylamino-1-hydroxy-3-phenylpropyl]-dihydro-furan-2-one (5c). The compound was prepared from 1c as described above (Method D, YbFOD). Purification by column chromatography (20% EtOAc in hexanes) gave 5c as a white solid (33%); mp 125–126 °C; [α]_D +35.7 (*c* 0.4, CHCl₃); ¹H NMR (CDCl₃) δ 0.88 (1H, m), 1.61 (1H, m), 1.80 (1H, s), 2.93 (1H, m), 3.13 (1H, m), 3.24 (1H, m), 3.40 (2H, d, *J* = 12.9 Hz), 3.78 (2H, d, *J* = 11.64 Hz), 3.92 (1H, dd, *J* = 8.94 and 7.47 Hz), 4.13 (1H, td, *J* = 8.70 and 2.28 Hz), 4.39 (1H, d, *J* = 9.4 Hz), 7.14–7.39 (15 H, m); ¹³C NMR (CDCl₃) δ 20.8, 31.4, 33.2, 43.8, 54.7, 61.8, 67.6, 71.9, 126.6, 127.6, 128.0, 128.7, 129.1, 129.3, 129.6, 129.8, 129.8, 139.9, 141.8, 180.6; IR (film) 3488, 3027, 2915, 1752; MS (FAB) *m/z* 416.2 [M + 1]⁺; HRMS calcd for C₂₇H₂₈NO₃ [M + 1]⁺ 416.2225; found 416.2229.

(3S)-3-[(1S,2S)-2-Dibenzylamino-1-hydroxy-3-phenylpropyl]-dihydro-furan-2-one (6c). The compound was isolated as the second isomer in the preparation of 5c. Purification by column chromatography (20% EtOAc in hexanes) gave 6c as a white solid (20%); mp 140–141 °C; [α]_D +51.7 (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.77 (1H, m), 1.09 (1H, m), 1.64 (1H, s), 2.75 (1H, m), 2.94 (1H, dd, *J* = 9.8 and 1.9 Hz), 3.17 (1H, m), 3.45 (2H, d, *J* = 13.1 Hz), 3.50 (1H, dd, *J* = 8.3 and 3.5 Hz), 3.84 (1H, m), 4.04 (1H, m), 4.23 (2H, m), 4.62 (1H, m), 7.19–7.36 (15 H, m); ¹³C NMR (CDCl₃) δ 25.6, 30.5, 41.2, 56.0, 60.7, 67.3, 73.1, 126.5, 127.5, 128.7, 128.8, 129.0, 129.8, 129.9, 140.5, 140.7, 181.5; IR (film) 3471, 3026, 1748; MS (FAB) *m/z* 416.2 [M + 1]⁺; HRMS calcd for C₂₇H₂₉NO₃ [M + 1]⁺ 416.2225; found 416.2223.

(3S)-3-[(1S,2S)-2-tert-Butoxycarbonylamino-1-hydroxy-4-methyl-pentyl]-dihydro-furan-2-one (6d). The compound was prepared from 1d as described above (Method D, YbFOD). Purification by column chromatography (30% EtOAc in hexanes) gave 6d as a white solid (71%); mp 96–97 °C; $[\alpha]_D - 48.9$ (c 0.6, CHCl₃); ¹H NMR (CDCl₃) δ 0.93 (3H, d, J = 2.4 Hz), 0.94 (3H, d, J = 2.4 Hz), 1.34 (1H, m), 1.44 (9H, s), 1.64 (2H, m), 2.26 (1H, m), 2.53 (1H, m), 2.75 (1H, td, J = 6.0 and 3.4 Hz), 3.10 (1H, b), 3.75 (1H, m), 4.05 (1H, s), 4.21 (1H, m), 4.39 (1H, td, J = 7.5 and 2.3 Hz), 4.66 (1H, d, J = 8.6 Hz); ¹³C NMR (CDCl₃) δ 22.4, 22.8, 23.6, 25.1, 28.7, 42.1, 44.7, 52.6, 67.7, 71.8, 80.0, 156.7, 179.3; IR (film) 3446, 2958, 2872, 1767, 1689, 1515; MS (EI) *m*/*z* 301.2 [M]⁺; HRMS calcd for C₁₅H₂₇-NO₅ [M]⁺ 301.1889; found 301.1898.

(4S)-4-Hydroxy-(3R)-(2-hydroxy-ethyl)-(5S)-5-isobutylpyrrolidin-2-one (7). To a solution of **3a** (43 mg, 0.11 mmol) in MeOH (1.0 mL) was added HCOOH (100 μ L). Pd-black (30 mg) was added, and the suspension was stirred at room temperature for 1.5 h. The catalyst was removed by filtration, and the filtrate was concentrated. The residue was dissolved in EtOAc, and the solution was washed with saturated NaHCO₃ and dried with Na₂SO₄. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (10% MeOH in CH₂Cl₂) to afford **7** as a colorless oil (15 mg, 70%): [α]_D -15.1 (c 0.8, CHCl₃); ¹H NMR (CDCl₃) δ 0.96 (6H, d, J = 6.1 Hz), 1.37 (1H, m), 1.69 (1H, m), 2.00 (1H, m), 2.62 (1H, m), 3.56 (1H, m), 3.75 (1H, m), 3.86 (1H, m), 3.93 (1H, m), 4.15 (1H, d, J = 16.1 Hz); ¹³C NMR (CDCl₃) δ 22.3, 23.6, 25.5, 26.9, 43.2, 45.9, 60.4, 62.0, 74.6, 178.6; IR (film); HRMS (FAB) calcd for $C_{10}H_{19}NO_3$ [M + 1] 201.14; found 201.14.

(3R)-3-[(1R,2S)-1-(tert-Butyl-dimethyl-silanyloxy-2-dibenzylamino-4-methyl-pentyl)]-dihydro-furan-2-one (9). To a solution of the alcohol 3a (312 mg, 0.82 mmol) in anhydrous CH₂Cl₂ (2 mL) at 0 °C was added 2,6-lutidine (202 μ L, 2.05 mmol) followed by TBSOTf (282 μ L, 1.23 mmol). The mixture was stirred at 0 °C for 1 h before it was quenched with aqueous NH₄Cl. The mixture was extracted with EtOAc $(3 \times 10 \text{ mL})$, and the combined organic phase was dried with Na₂SO₄ and concentrated. The residue was purified by column chromatography (10% EtOAc in hexanes) to afford 9 as a crystalline solid (390 mg, 96%); mp 93–94 °C; [α]_D +9.4 (c 0.8, CH₂Cl₂); ¹H NMR (CDCl₃) δ 0.00 (3H, s), 0.10 (3H, s), 0.60 (1H, m), 0.85 (9H, s), 1.02 (6H, m), 1.58 (3H, m), 1.98 (1H, m), 2.52 (2H, m), 3.33 (1H, t, J = 10.2 Hz), 3.48 (2H, d, J = 13.0Hz), 3.77 (2H, d, J = 13.6 Hz), 3.79 (1H, m), 4.13 (2H, m), 7.27 (10 H, m); ¹³C NMR (CDCl₃) δ -3.8, -3.6, 18.6, 20.4, 23.0, 24.1, 26.3, 26.6, 37.3, 43.7, 54.8, 58.1, 67.3, 72.7, 127.5, 128.7, 130.1, 140.4, 180.6; IR (film) 3064, 2956, 2858, 1770; MS (FAB) m/z 496.3 [M + 1]⁺; HRMS calcd for C₃₀H₄₄NO₃Si [M + 1]⁺ 496.3246; found 496.3251.

(3S)-3-[(1S,2S)-1-(*tert*-Butyl-dimethyl-silanyloxy-2-dibenzylamino-4-methyl-pentyl)]-dihydro-furan-2-one (10). The compound was prepared from 4a or 6a as a colorless oil (95%); $[\alpha]_D - 34.2$ (c 0.95, CHCl₃); ¹H NMR (CDCl₃): $\delta - 0.10$ (3H, s), -0.07 (3H, s), 0.82 (9H, s), 0.95 (6H, m), 1.49 (1H, m), 1.61 (2H, m), 1.77 (1H, m), 2.32 (1H, m), 2.36 (1H, m), 2.59 (1H, m), 2.68 (1H, m), 3.48 (2H, d, J = 13.4 Hz), 3.98 (2H, d, J = 13.4 Hz), 4.10 (1H, m), 4.28 (1H, m), 4.33 (1H, m), 7.30 (10 H, m); ¹³C NMR (CDCl₃): $\delta - 4.1$, 14.6, 18.6, 23.1, 23.5, 23.5, 24.2, 25.7, 26.1, 26.4, 26.6, 32.0, 34.1, 44.6, 55.8, 60.4, 67.3, 72.3, 127.4, 128.5, 128.7, 129.4, 130.1, 140.7, 180.0; IR (film) 3028, 2930, 2857, 1770; MS (FAB) m/z 496.2 [M + 1]+; HRMS calcd for C₃₀H₄₆ NO₃Si [M + 1]+ 496.3246; found 496.3247.

(2S)-2-[(1S,2S)-1-(tert-butyl-dimethyl-silanyloxy)-2dibenzylamino-4-methyl-pentyl]-(1S)-1-[1,3]dithian-2yl-butane-1,4-diol (12). To a solution of 1,3-dithiane (92 mg, 0.76 mmol) in anhydrous THF (4 mL) was added n-butyllithium (2.5 M in hexane) (278 μ L, 0.70 mmol) under Ar at -78 °C. After 30 min, the solution was transferred by cannula to a solution of lactone 10 (156 mg, 0.32 mmol) in THF (4 mL) at -78 °C. The reaction mixture was stirred at -78 °C for a further 40 min before it was quenched with saturated NH₄Cl and allowed to warm to room temperature. The mixture was extracted with EtOAc (3×10 mL), the combined organic phase was dried by Na₂SO₄ and concentrated under reduced pressure, and the residue was purified by column chromatography (10% EtOAc in hexanes) to afford a mixture of ketone 11a and lactols 11b,c (131 mg). The mixture of products was dissolved in anhydrous methanol, and NaBH₄ (21 mg, 0.53 mmol) was added in small portions at room temperature. The solution was stirred until the disappearance of starting material by TLC (about 1 h) and quenched with water. The solvent was removed under reduced pressure, and the residue was extracted by EtOAc (3×10 mL). Purification by column chromatography (20% EtOAc in hexanes) gave diol 12 as a foamy white solid (113 mg, 58%); mp 48–50 °C; $[\alpha]_D$ –19.5 (c 0.4, CH₂Cl₂); ¹H NMR (CDCl₃) & 0.04 (3H, s), 0.17 (3H, s), 0.82 (2H, m), 0.87 (9H, s), 0.98 (3H, d, J = 6.0), 1.02 (3H, d, J = 6.0), 1.50 (2H, d)m), 1.74 (2H, m), 2.02 (2H, m), 2.20 (1H, m), 2.69 (2H, m), 2.90 (3H, m), 3.28 (2H, d, J = 13.08), 3.51 (2H, m), 3.83 (1H, d, J = 2.55), 3.91 (1H, d, J = 2.13), 4.16 (1H, b), 4.41 (2H, d, J = 8.34), 4.80 (1H, b), 7.30 (10 H, m); ¹³C NMR (CDCl₃) δ -4.6, -3.3, 14.1, 14.6, 18.6, 19.5, 21.5, 22.5, 24.6, 25.8, 26.5,26.5, 26.7, 30.2, 31.0, 31.2, 33.5, 42.5, 53.1, 56.2, 61.5, 64.8, 75.2, 76.3, 77.6, 127.3, 127.5, 128.7, 129.4, 130.6, 139.7, 139.9;IR (film) 3469, 3028, 2954, 2857, 1453; MS (FAB) m/z 618.3 $[M + 1]^+$; HRMS calcd for $C_{34}H_{56}NO_3S_2Si [M + 1]^+ 618.3470$; found 618.3482.

(S)-Dibenzyl-(3S)-[(1S)-1-tert-butyl-dimethyl-silanyloxy)-(2S)-2-[1,3]dithian-2-yl-tetrahydro-furan-3-yl)-methyl]-3methyl-butyl]-amine (13). To a solution of diol 12 (12 mg, 0.020 mmol) in anhydrous THF (1 mL), PPh₃ (21 mg, 0.076 mmol) was added, and a solution of DEAD (12 mg, 1.006 mmol) in THF (1 mL) was added dropwise. The reaction mixture was stirred at room temperature for 3 h, the solvent was removed under reduced pressure, and the residue was purified by column chromatography (10% EtOAc in hexanes) to give 13 as white crystals (12 mg, 87%); $[\alpha]_{\rm D}$ +16.3 (c 0.6, CH_2Cl_2); $^1\mathrm{H}$ NMR (CDCl₃) & 0.08 (3 H, s), 0.09 (3 H, s), 0.80 (9 H, s,), 1.03 (3 H, d, J = 6.5 Hz), 1.08 (3 H, d, J = 6.3 Hz), 1.45 (1 H, m),1.65 (1 H, m), 1.81 (2 H, m), 1.96 (3 H, m), 2.35 (2 H, d, J = 8.7 Hz), 2.47 (1 H, m), 2.68 (2 H, m), 2.77 (2 H, m), 3.19 (1 H, m), 3.27 (2 H, d, J = 12.9 Hz), 3.58 (1 H, m), 3.63 (1 H, m), 4.00 (2 H, m), 4.11 (2 H, d, J = 9.5 Hz), 7.26 (10 H, m); ¹³C NMR (CDCl₃) δ -2.9, -2.7, 18.9, 22.9, 24.6, 25.7, 25.9, 26.7, 30.6, 31.0, 31.5, 33.6, 46.1, 51.5, 56.4, 57.7, 69.0, 73.8, 77.6, 80.6, 127.4, 128.6, 129.7, 141.1; IR (film) 3028, 2954, 2857, 1454; MS (FAB) m/z 600 [M + 1]⁺; HRMS calcd for $C_{34}H_{54}$ - $NO_2S_2Si [M + 1]^+ 600.3365$; found 600.3391.

(3S)-3-[(1S)-1-tert-Butyl-dimethyl-silanyloxy)-(2S)-2dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2S)-2-carbaldehyde (14). An amount of 13 (55 mg, 0.092 mmol) was dissolved in a mixture of THF-H₂O (9:1, 2 mL), a mixture of red HgO (40 mg, 0.184 mmol) and BF₃ etherate (23.2 μ L, 0.184 mmol) in THF (1 mL) were added, and the resulting mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (3 \times 10 mL), and the organic phase was dried with Na₂- SO_4 and concentrated. The residue was purified by column chromatography (10% EtOAc in hexanes) to afford 14 as a colorless oil (38 mg, 84%); $[\alpha]_{\rm D}$ +8.0 (c 0.9, CH_2Cl_2); ¹H NMR (CDCl₃): δ 0.00 (3 H, s), 0.06 (3 H, s), 0.81 (9 H, s), 0.93 (2H, m), 1.03 (6 H, q, J = 4.4 and 6.2 Hz), 1.45 (2 H, m), 1.66 (2 H, m), 2.11 (1 H, m), 2.41 (1 H, m), 2.56 (1 H, m, J = 9.8 Hz), 3.23 (1 H, m), 3.30 (2 H, d, J = 13.1 Hz), 3.75 (1 H, dd, J =10.0 and 1.6 Hz), 3.86 (2 H, m), 4.11 (2 H, m), 7.28 (10 H, m), 9.31 (1 H, d, J = 2.0 Hz); ¹³C NMR (CDCl₃): δ -3.3, -2.9, 18.9, 22.7, 24.5, 25.3, 26.6, 31.1, 33.3, 47.8, 56.2, 57.3, 69.2, 73.8, 76.9, 82.2, 127.4, 128.6, 129.2, 129.4, 129.9, 130.2, 134.8, 141.2, 203.8; IR (film) 3085, 3063, 3028, 2955, 2928, 2857, 1730; MS (FAB) m/z 510 [M + 1]⁺; HRMS calcd for C₃₁H₄₈NO₃Si [M + 1]⁺ 510.3403; found 510.3389.

(3S)-3-[(1S)-1-tert-Butyl-dimethyl-silanyloxy)-(2S)-2dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2S)-2-carboxylic acid methyl ester (15). To a solution of the aldehyde 14 (34 mg, 0.067 mmol) and 2-methyl-2-butene (86 μ L, 0.80 mmol) in a mixture of *t*-BuOH/CH₃CN (0.8 mL 5:3) was added dropwise a solution of NaClO₂ (45 mg, 0.34 mmol), and NaH_2PO_4 dihydrate (64 mg, 0.34 mmol) in water (0.67 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 0 $^\circ\mathrm{C}$ for 0.5 h and quenched with 5% aqueous $Na_2S_2O_3$ (0.67 mL), and a few drops of 1% HCl were added to pH 6. The mixture was extracted with EtOAc (3 \times 5 mL). The combined organic phase was dried with Na₂SO₄ and concentrated, and the crude acid was dissolved in CH₂Cl₂ (2 mL) and cooled to 0 °C. An ethereal solution of CH₂N₂ was added until the yellow color of the solution persisted. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (10% EtOAc in hexanes) to give ester 15 as a colorless oil (18 mg, 52%); $[\alpha]_{\rm D}$ +57.86 (c 0.8, CH₂Cl₂); ¹H NMR (CDCl₃) & 0.04 (3 H, s), 0.08 (3 H, s,), 0.82 (9H, s), 1.00 (1 H, d, J = 4.3 Hz), 1.05 (1 H, d, J = 4.5 Hz), 1.47 (2 H, m), 1.72 (1 H, m), 1.92 (1 H, m), 2.09 (1 H, m), 2.49 (1 H, d, J = 9.9 Hz), 2.56 (1 H, d, J = 7.5 Hz), 3.26 (2 H, d, J)= 13.0 Hz), 3.33 (1H, m), 3.48 (1 H, d, J = 10.1 Hz), 3.54 (3H, s), 3.82 (1 H, m), 4.12 (1 H, m), 7.30 (10 H, m); $^{13}\mathrm{C}$ NMR (CDCl₃) δ -3.2, -2.9, 18.9, 22.5, 24.5, 25.4, 26.6, 29.7, 33.4, 46.8, 51.5, 56.3, 57.3, 69.1, 74.9, 127.3, 128.5, 129.9, 173.3; IR (film): 3063, 3028, 2954, 2858, 1738; MS (FAB) m/z 540.3 [M + 1]+; HRMS calcd for $\rm C_{32}H_{50}NO_4Si$ [M + 1]+ 540.3509; found 540.3488.

 $(3S) \hbox{-} 3 \hbox{-} [(1S) \hbox{-} 1 \hbox{-} tert \hbox{-} Butyl \hbox{-} dimethyl \hbox{-} silanyloxy) \hbox{-} (2S) \hbox{-} 2 \hbox{-}$ dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2S)-2-carboxylic Acid (17). A solution of 15 (190 mg, 0.35 mmol) in NaOMe (25% in weight in MeOH, 1 mL) was refluxed at 70 °C for 6 h. Water (100 μ L) was added, and the mixture was stirred at room temperature 12 h. The reaction mixture was acidified with HCl (5N, 3.5 mL) to pH 3 and extracted with EtOAc $(3 \times 20 \text{ mL})$, and the organic phase was dried with Na₂-SO₄ and concentrated. The residue was purified by column chromatography (75% of EtOAc in hexanes) to afford 17 as a colorless oil (82 mg, 80%); [α]_D –15.1 (*c* 0.6, CHCl₃); ¹H NMR (CDCl₃) δ -0.36 (3 H, s), -0.03 (3H, s,), 0.83 (9H, s), 0.91 (6H, d, J = 6.4 Hz), 1.54 (2H, m), 1.85 (1H, m), 2.05 (1H, m), 2.16 (1H, m), 2.56 (1H, m), 2.91 (1H, m), 3.65 (2H, d, J = 13.6 Hz), 3.94 (2H, d, J = 13.6 Hz), 4.08 (1H, d, J = 8.16 Hz, 8.2 Hz),7.19–7.42 (10 H, m); $^{13}\mathrm{C}$ NMR (CDCl₃) δ –4.6, –3.9, 18.5, 22.6, 24.0, 25.7, 25.9, 26.4, 28.4, 34.8, 47.7, 55.7, 59.5, 70.1, 72.2, 79.5, 127.6, 128.8, 129.4, 139.6, 176.8; IR (film) 3583 (b), 3063, 3028, 2954, 2856, 1722; MS (FAB) m/z 525 [M + 1]⁺; HRMS calcd for $C_{31}H_{47}NO_4Si [M + 1]^+ 525.3274$; found 525.3282.

(3S)-3-[(1S)-1-tert-Butyl-dimethyl-silanyloxy)-(2S)-2dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2R)-2-carboxylic Acid Butylamide (18a). To a solution of acid 17 (30 mg, 0.057 mmol) and *n*-butylamine (15 μ L, 0.152 mmol) in CH₂Cl₂ (2 mL) was added PyBop (30 mg, 0.057 mmol) at 0 °C followed by *i*-Pr₂NEt (39 μ L, 0.23 mmol). The reaction mixture was stirred at 0 °C to room temperature for 14 h, and then it was diluted with EtOAc (5 mL) and washed with aqueous 1 N HCl and saturated NaHCO₃. The organic phase was dried with Na₂SO₄ and concentrated, and the residue was purified by column chromatography (10% EtOAc in hexanes) to afford **18a** as a colorless oil (28 mg, 80%); $[\alpha]_D - 41.4$ (c 1.15, CH₂Cl₂); ¹H NMR (CDCl₃): δ -0.42 (3 H, s), 0.00 (3 H, s), 0.82 (9 H, s), 0.86 (3 H, d, J = 5.9 Hz), 0.95 (6 H, m), 1.37 (2 H, m), 1.52 (4 H, m), 1.65 (1 H, m), 1.92 (2 H, m), 2.30 (2 H, m), 2.84 (1 H, m), 3.30 (1 H, m), 3.69 (2 H, d, J = 13.8 Hz), 3.81 (2 H, 3.81 (2 H, 3.81 Hz))m), 3.86 (2 H, d, J = 13.8 Hz), 3.96 (1 H, d, J = 8.4 Hz), 4.46 (1 H, m), 6.59 (1 H, m), 7.21 (2 H, m), 7.31 (4 H, m), 7.43 (4 H, m);¹³C NMR (CDCl₃): δ -4.5, -4.0, 14.2, 18.5, 20.5, 22.4, 24.6, 25.6, 26.4, 27.5, 32.2, 35.6, 38.7, 47.8, 55.4, 59.6, 69.7, 71.4, 78.3, 80.7, 127.2, 128.6, 129.2, 140.9, 173.2; IR (film) 3424, 3063, 2955, 2929, 2857, 1675, 1524; MS (FAB) m/z 581.4 [M $(+1)^+$; HRMS calcd for $C_{35}H_{57}N_2O_3Si [M + 1]^+ 581.4131$; found 581.4138.

(3S)-3-[(1S)-1-tert-Butyl-dimethyl-silanyloxy)-(2S)-2dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2R)-2-carboxylic Acid N-Methyl-L-ala Amide (18b). Boc-Lalanine methylamide (17 mg, 0.085 mmol) was stirred with HCl in dioxane (4M, 1 mL) for 0.5 h and was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (2 mL). To the solution, acid 17 (30 mg, 0.057 mmol), PyBop (30 mg, 0.057 mmol), and *i*-Pr₂NEt (39 μ L, 0.23 mmol) were added at 0 °C. The reaction mixture was stirred at 0 °C to room temperature for 14 h, and then it was diluted with EtOAc (10 mL). The organic phase was washed with aqueous 1 N HCl and saturated NaHCO₃. The organic phase was dried and concentrated. The residue was purified with column chromatography (20% EtOAc in hexanes) to afford 18b as a colorless oil (22 mg, 63%); [α]_D –40.4 (*c* 0.9 in CHCl₃); ¹H NMR (CDCl₃): $\delta - 0.04$ (3H, s), 0.01 (3H, s), 0.82 (9H, s), 0.86 (2H, m), 0.93 (3 H, d, J = 6.0 Hz), 1.26 (1H, m), 1.42 (3 H, d, J = 6.8 Hz), 1.50 (1 H, m), 1.93 (2 H, m), 2.29 (2 H, m), 2.69 (2 H, d, J = 4.6Hz), 2.84 (1 H, m), 3.70 (2 H, d, J = 13.7 Hz), 3.81 (2 H, d, J= 13.7 Hz), 3.91 (1 H, m), 4.01 (1H, m), 4.46 (1H, m), 6.19 (1 H, m), 7.02 (1 H, m), 7.21 (2 H, m), 7.29 (4 H, m), 7.43 (4 H, m); 13 C NMR (CDCl₃) δ -4.5, -4.0, 14.2, 18.5, 20.6, 22.4, 24.6, 25.7, 26.4, 27.5, 32.2, 35.6, 38.7, 47.8, 55.4, 59.6, 69.7, 71.4, 78.3, 80.7, 127.2, 128.6, 129.2, 140.9, 173.2; IR (film) 3324,

3063, 2954, 2931, 2858, 1655, 1513; MS (FAB) $m/z\,$ 610.4 [M + 1]+; HRMS calcd for $\rm C_{35}H_{56}N_3O_4Si\,\,[M$ + 1]+ 610.4040; found 610.4024.

 $(3S) \hbox{-} 3 \hbox{-} [(1S) \hbox{-} 1 \hbox{-} tert \hbox{-} Butyl \hbox{-} dimethyl \hbox{-} silanyloxy) \hbox{-} (2S) \hbox{-} 2 \hbox{-}$ dibenzylamino-4-methyl-pentyl]-tetrahydro-furan-(2R)-2-carboxylic Acid N-Butyl-L-Val Amide (18c). Boc-L-valine n-butylamide (49 mg, 0.18 mmol) was stirred with HCl in dioxane (4 M, 1 mL) for 1 h. After removing the solvent under reduced pressure, the compound was dissolved in CH₂Cl₂ (2 mL) and cooled to 0 °C. The acid 17 (63 mg, 0.12 mmol) was added followed by PyBOP (65 mg, 0.12 mmol) and *i*-Pr₂NEt (65 μ L, 0.375 mmol). The reaction mixture was stirred from 0 °C to room temperature for 3 h before it was diluted with EtOAc (10 mL) and washed with aqueous 1 N HCl and saturated NaHCO₃. The organic phase was dried and concentrated, and the residue was purified by column chromatography (20% EtOAc in hexanes) to afford 18c as a colorless oil (64 mg, 79%); [a]_D –37.9 (c 0.42, CHCl_3); ¹H NMR (CDCl_3) δ 0.83 (3H, t, J = 7.2 Hz), 1.23 (2H, m), 1.28 (3H, d, J = 7.0Hz), 1.37 (9H, s), 1.41 (2H, m), 3.15 (2H, m), 4.14 (1H, m), 5.44 (1H, d, J = 7.7 Hz), 6.72 (1H, b); ¹³C NMR (CDCl₃) δ -4.6, -3.9, 14.0, 18.5, 18.8, 19.7, 20.4, 22.3, 24.6, 25.4, 26.3, 27.4,30.9, 31.9, 35.4, 39.6, 48.2, 54.9, 58.8, 59.5, 69.9, 71.0, 80.7, 127.2, 128.6, 129.1, 140.9, 171.2, 173.8; IR (film) 3308, 2964, 2956, 2859, 16519, 1515; MS (FAB) m/z 680.5 [M + 1]⁺; HRMS calcd for $C_{40}H_{66}N_{3}O_{4}Si\ [M+1]^{+}$ 680.4822; found 680.4791.

(3S)-3-[(1S)-1-Hydroxyl)-(2S)-2-tert-butoxycarbonylamino]-tetrahydro-furan-(2R)-2-carboxylic Acid Butylamide (19a). To a solution of 18a (28 mg, 0.048 mmol) in HCOOH/ MeOH (5%) (1 mL) at room temperature was added Pd-black (28 mg), and the suspension was stirred for 1 h. The solid was filtered, and the solution was concentrated to dryness. The residue was dissolved in MeOH (2.0 mL), and Boc₂O (52.3 mg, 0.24 mmol) and NaHCO₃ (200 mg) were added. The mixture was stirred at room temperature for 14 h, the solid was filtered, and the solution was concentrated to dryness. The residue was treated with TBAF (1.0 M in THF, 0.5 mL) at 0 °C for 0.5 h before it was taken up by EtOAc (10 mL). The EtOAc solution was washed with water and concentrated. The residue was purified by column chromatography (50% EtOAc in hexanes) to give **19a** as a colorless oil (14 mg, 77%); $[\alpha]_D$ +3.02 (c 0.4, CH₂Cl₂); ¹H NMR (CDCl₃) δ 0.92 (9 H, m), 1.33 (3 H, m), 1.43 (9 H, s), 1.51 (2H, m), 1.67 (3H, m), 2.00 (1 H, m), 2.10 (1 H, m), 2.40 (1 H, m), 3.26 (2 H, m), 3.64 (1 H, m), 3.77 (1 H, m), 3.83 (1 H, m), 3.98 (1 H, m), 4.10 (1 H, d, J = 5.7 Hz), 4.18 (1 H, d, J = 7.7 Hz), 5.11 (1 H, d, J = 8.3 Hz), 6.74 (1 H, m); ¹³C NMR (CDCl₃) δ 14.1, 20.4, 22.4, 23.7, 25.2, 28.2, 28.8, 31.9, 38.9, 41.7, 48.5, 52.4, 69.2, 74.3, 79.8, 79.8, 157.4, 173.8; IR (film) 3329, 2957, 2871, 1688, 1661, 1531; MS (FAB) m/z 387.2 [M + 1]⁺; HRMS calcd for C₂₀H₃₉N₂O₃Si [M + 1]⁺ 387.2858; found 387.2840.

(3S)-3-[(1S)-1-tert-Butyl-dimethyl-silanyloxy)-(2S)-2tert-butoxycarbonylamino-4-methyl-pentyl]-tetrahydrofuran-(2R)-2-carboxylic Acid N-Methyl-L-ala Amide (19b). By a similar procedure 19b was prepared and purified by column chromatography to give a colorless oil (10% hexanes in EtOAc) (13 mg, 91%); [α]_D -33.0 (*c* 0.40, CHCl₃); ¹H NMR (MeOD) δ 0.91 (6H, m), 1.39 (2H, m), 1.40 (3 H, d, J=7.0Hz), 1.42 (9H, s), 1.62 (3 H, m), 1.97 (1 H, m), 2.10 (1 H, m), 2.37 (1 H, m), 2.82 (2 H, d, J = 4.7 Hz), 3.62 (2 H, m), 3.75 (1 H, m), 3.88 (2H, m), 3.98 (1H, m), 4.21 (2 H, d, J = 7.8 Hz), 4.41 (1 H, m), 4.99 (2 H, d, J = 8.9 Hz), 6.18 (1 H, m), 7.23 (2 H, d, J = 7.2 Hz); $^{13}\mathrm{C}$ NMR (MeOD) δ 14.2, 18.4, 20.8, 22.3, 23.7, 25.2, 26.7, 27.5, 28.7, 41.5, 48.4, 48.7, 52.7, 52.9, 69.5, 74.1, 79.7, 80.0, 157.3, 172.8, 174.0; IR (film) 3324, 2956, 1652, 1520; MS (FAB) calcd for $C_{20}H_{38}N_3O_6 m/z$ 416.2 [M + 1]⁺; HRMS found, 416.28.

Compound 20a. Compound **19a** (14 mg, 0.036 mmol) was stirred with HCl in dioxane (4 M, 0.5 mL) for 1 h at room temperature. The mixture was concentrated to dryness under reduced pressure, and the residue was dissolved in CH_2Cl_2 (1.0 mL). The solution was cooled to 0 °C, and N'-trityl-BocAspOH

(25.6 mg, 0.054 mmol) was added followed by PyBop (18.8 mg, 0.036 mmol) and *i*-Pr₂NEt (23 μ L, 0.14 mmol). The mixture was stirred at 0 °C to room temperature for 2 h before it was diluted with EtOAc (5 mL), and the organic phase was washed with aqueous 1 N HCl and NaHCO₃. The organic phase was dried and concentrated, and the residue was purified by column chromatography (30% hexanes in EtOAc) to give 20a as a white solid (27 mg, 99%); $[\alpha]_D$ –9.04 (c 0.8, CHCl₃); ¹H NMR (CDCl₃) δ 0.88 (6H, dd, J = 0.3 and 0.5 Hz), 0.92 (3 H, t, J = 7.3 Hz), 1.34 (3H, m), 1.43 (9 H, s), 1.48 (2 H, m), 1.58 (2 H, m), 1.85 (1 H, m), 2.02 (1 H, m), 2.38 (1 H, m), 2.62 (1 H m), 2.90 (1 H, s), 3.00 (1 H, m), 3.10 (1 H, m), 3.27 (1 H, m), 3.66 (2 H, m), 3.83 (1 H, m), 3.90 (1 H, m), 4.08 (1 H, d, J = 7.3 Hz), 4.14 (1 H, d, J = 6.3 Hz), 4.36 (1 H, m), 6.08 (1 H, d, J = 7.8 Hz), 6.64 (1 H, t, J = 5.6 Hz), 6.99 (1 H, m), 7.07 (1 H, d, J = 8.4 Hz), 7.17–7.31 (15H, m); ¹³C NMR (CDCl₃) δ 14.1, 20.4, 21.5, 22.4, 23.6, 25.2, 28.4, 28.6, 31.9, 38.3, 38.8, 40.3, 47.9, 52.0, 52.9, 60.8, 69.3, 71.1, 74.8, 127.5, 128.4, 129.1, 144.8, 156.3, 170.6, 172.9, 173.5; IR (film) 3326, 2958, 1657, 1526; MS (FAB) m/z 743.9 [M + 1]⁺; HRMS calcd for C₄₃H₅₈N₄O₇ $[M + 1]^+$ 743.4364; found 743.4383.

Compound 20b. By a similar procedure **20b** was prepared from **19b**. Purification by column chromatography (10% MeOH in EtOAc) gave **20b** as a white solid (17 mg, 71%); $[\alpha]_D -28.4$ (*c* 0.7, CHCl₃); ¹H NMR (MeOD) δ 0.88 (6H, m), 1.25–1.49 (4 H, m), 1.32 (3H, d, J = 6.6 Hz), 1.42 (9 H, s), 1.61 (2 H, m), 1.84 (1 H, m), 1.99 (1 H, m), 2.33 (1 H, m), 2.62 (3 H, d, J = 3.8 Hz), 2.69 (1 H, m), 2.95 (1 H, m), 3.62 (1 H, m), 3.84 (3 H, m), 4.06 (1 H, m), 4.36 (2 H, m), 6.14 (1 H, b), 6.29 (1 H, b), 6.96 (1 H, b), 7.26 (15 H, m); ¹³C NMR (MeOD) δ 18.6, 22.3, 23.7, 25.1, 26.6, 27.8, 28.6, 38.5, 40.4, 47.9, 48.7, 52.2, 52.6, 69.3, 71.1, 74.4, 77.6, 79.7, 80.7, 127.5, 128.4, 129.1, 144.7, 156.2, 170.7, 172.7, 172.9, 173.9; IR (film) 3318, 2956, 1651, 1519; MS (FAB) *m/z* 772.4 [M + 1]⁺; HRMS calcd for C₄₃H₅₈N₅O₈ [M + 1]⁺ 772.4298; found 772.4285.

Compound 20c. Compound 18c (56 mg, 0.082 mmol) was dissolved in HCOOH/MeOH (5%) (4 mL), Pd-black (56 mg) was added, and the suspension was stirred for 1 h. The catalyst was filtered, the solvent was removed under reduced pressure, and the residue was redissolved in EtOAc and washed with 1 N NaHCO. The organic phase was dried and concentrated, and the residue was stirred with Boc₂O (89.38 mg, 0.41 mmol) and NaHCO₃ (300 mg) in MeOH (3 mL) overnight. After removal of the solid and the solvent, the residue was treated with TBAF (1.0 M in THF, 1.5 mL, predried with molecular seives) at 0 °C for 1.5 h. The reaction mixture was diluted with EtOAc (10 mL), washed with water, and dried with Na₂SO₄. After concentration, the residue was purified by column chromatography (50% EtOAc in hexanes) to give 19c (34 mg, 83%). The compound was stirred with HCl in dioxane (4 M, 1 mL) at room temperature for 1 h. After removing the solvent under reduced pressure, the residue was dissolved in CH₂Cl₂ (1.5 mL) and cooled to 0 °C. N-Boc-L-MetOH (20.3 mg, 0.082 mmol) was added, followed by PyBOP (42.4 mg, 0.082 mmol) and i-Pr2-NEt (35 μ L, 0.204 mmol). The reaction mixture was stirred from 0 °C to room temperature for 3 h before it was diluted with EtOAc (10 mL) and washed with aqueous 1 N HCl and saturated NaHCO₃. The organic phase was dried and concentrated, and the residue was purified by column chromatography (40% hexanes in EtOAc) to give **20c** was as a colorless oil (18 mg, 43%); $[\alpha]_D$ –38.4 (c 0.69, MeOH); ¹H NMR (CDCl₃) δ 0.92 (9H, m), 1.33 (3H, m), 1.36 (3H, d, J = 6.9 Hz), 1.45 (12H, s), 1.48 (2H, m), 1.58 (3H, s), 1.64 (4H, m), 1.67 (2H, m), 1.72 (1H, m), 1.88 (1H, m), 2.37 (1H, m), 2.47 (1H, m), 3.24 (2H, dd, J = 6.7 and 13.1 Hz), 3.63 (1H, m), 3.74 (1H, m), 4.52 (1H, t, $J=7.0~{\rm Hz}),\,6.40~(1{\rm H},\,{\rm t},\,J=6.8~{\rm Hz}),\,6.63~(1{\rm H},\,{\rm b});\,^{13}{\rm C}~{\rm NMR}$ $(CDCl_3)$ δ 13.1, 13.3, 14.2, 17.7, 18.7, 20.1, 20.6, 21.3, 22.9, 24.7, 26.2, 27.7, 27.8, 30.3, 31.4, 31.5, 31.6, 39.1, 41.4, 51.6, 53.6, 54.5, 58.5, 69.1, 71.8, 79.7, 80.1, 156.8, 172.1, 173.7, 174.4; IR (film) 3304, 2960, 2932, 2872, 1651, 1525; MS (FAB) calcd for $C_{30}H_{56}N_4O_7S m/z [M + 1]^+ 617.4$; found 617.42.

Compound 21a. Compound 20a (12 mg, 0.017 mmol) was stirred with HCl in dioxane (4 M, 0.5 mL) for 1 h at room temperature. The mixture was concentrated to dryness under reduced pressure, and the residue was dissolved in a mixture of CH₂Cl₂ (0.5 mL) and water (0.5 mL). The solution was cooled to 0 °C, and N-Ac-L-ValOH (2.7 mg, 0.017 mmol) was added followed by HOBt (2.3 mg, 0.017 mmol) and EDC (3.8 mg 0.018 mmol). The reaction mixture was stirred at 0 to 5 °C for 24 h, and then it was diluted with EtOAc (5 mL). The organic phase was washed with aqueous 1 N HCl, aqueous 1 N NaHCO₃, and brine. The organic phase was dried and concentrated, and the residue was purified by column chromatography (20% MeOH in CH_2Cl_2) to give the peptide product (14 mg). This was stirred with TFA/water (95:5, 0.5 mL) at room temperature for 1 h, MeOH (3 mL) was added, and the reaction mixture was concentrated at room temperature to dryness under reduced pressure. The residue was taken up with EtOAc (5 mL) and washed with aqueous NaHCO₃ and brine. The organic phase was dried and concentrated, and the residue was purified by column chromatography (20% MeOH in CH₂Cl₂) to give **21a** as a white solid (8 mg, 61%); $[\alpha]_D = -24.1$ (*c* 0.34, MeOH); ¹H NMR (CDCl₃) & 0.87-1.02 (15H, m), 1.38 (3 H, m), 1.50 (3H, m), 1.60 (3 H, m), 1.85 (1 H, m), 2.02 (3 H, s), 2.09 (1 H, m), 2.33 (1 H, m), 2.74 (1 H, m), 3.20 (2 H, t, J = 7.1 H)Hz), 3.77 (1 H, m), 3.93 (2 H, m), 4.14 (2 H, dd, J = 6.8 Hz), 4.66 (1 H, t, J = 5.4 Hz); ¹³C NMR (CDCl₃) δ 13.1, 17.6, 18.6, 20.1, 21.2, 21.4, 22.9, 24.6, 25.9, 30.4, 31.6, 36.4, 38.6, 41.1, 48.3, 50.9, 52.1, 59.9, 69.1, 72.2, 80.3, 171.6, 172.6, 172.8, 174.2, 174.7; IR (film) 3308, 2959, 1635, 1451; MS (FAB) m/z 542.3 $[M + 1]^+$; HRMS calcd for $C_{26}H_{47}N_5O_7$ $[M + 1]^+$ 542.3553; found 542.3542.

Compound 21b. By a similar procedure **21b** was prepared from **20b**. Purification by column chromatography gave **21b** as an white solid (5.2 mg, 66%); $[\alpha]_D$ -34.0 (*c* 0.20, MeOH); ¹H NMR (CDCl₃): δ 0.88 (3 H, d, J = 6.5 Hz), 0.91 (3 H, d, J = 6.5 Hz), 0.97 (6 H, d, J = 6.3 Hz), 1.29 (2 H, m), 1.36 (3 H, d, J = 7.1 Hz), 1.54 (1H, m), 1.61 (1 H, m), 1.90 (1 H, m), 2.02 (3 H, s), 2.09 (1 H, m), 2.39 (1 H, m), 2.74 (3 H, s), 2.75 (1 H, m), 3.71 (1 H, t, J = 4.4 Hz), 3.95 (2 H, m), 4.00 (1 H, m), 4.10 (1 H, d, J = 6.4 Hz), 4.23 (1 H, d, J = 6.4 Hz), 4.35 (1 H, q, J = 7.1 Hz), 4.66 (1 H, t, J = 6.5 Hz); ¹³C NMR (CDCl₃) δ 13.4, 17.7, 18.6, 21.2, 21.4, 22.9, 24.6, 25.4, 26.1, 30.4, 36.4, 40.8, 48.9, 50.1, 50.9, 51.8, 59.9, 69.1, 72.3, 80.1, 171.7, 172.6, 172.9, 174.1, 174.3, 174.4; IR (film) 3307, 2964, 1673, 1536. MS (FAB) m/z 571.1 [M + 1]⁺, 593.1 [M + 23]⁺; HRMS calcd for C₂₆H₄₇N₆O₈ [M + 1]⁺ 571.3455; found 571.3436.

Compound 21c. Compound 20c (13 mg, 0.021 mmol) was treated with HCl in dioxane (4 M, 1 mL) for 1 h. After removing the solvent under reduced pressure, the residue was dissolved in EtOAc and washed with 1 N NaHCO₃ and water. The solvent was evaporated, and the residue was dissolved in CH2Cl2/water (1:1) (1.0 mL) and cooled to 0 °C. N-Ac-LeuOH (7.23 mg, 0.042 mmol) was added, followed by EDC (9 mg, 0.042 mmol) and HOBT (5.6 mg, 0.042 mmol). The reaction mixture was stirred from 0 to 5 °C for 24 h. The reaction mixture was diluted with EtOAc (5 mL) and washed with aqueous 1 N HCl and 1 N NaHCO $_3$. The organic phase was dried and concentrated, and the residue was purified by column chromatography (10% MeOH in CH₂Cl₂) to give 21c as a white solid (13 mg, 92%). $[\alpha]_{\rm D}$ –49.1 (c 0.6, MeOH); 1H NMR (CDCl₃) δ 0.91 (9H, m), 1.34 (3H, m), 1.37 (3H, d, J =7.2 Hz), 1.43 (9H, s), 1.47 (2H, m), 1.63 (4H, m), 1.74 (2H, m), 1.88 (2H, m), 1.91 (2H, m), 2.10 (3H, s), 2.36 (1H, m), 2.38 (1H, m), 2.57 (2H, m), 3.21 (2H, m), 3.28 (1H, m), 3.40 (1H, m), 4.22 (1H, q, J = 7.0 Hz), 4.31 (1H, t, J = 6.4 Hz), 5.0 (1H, b), 5.26 (1H, d, J = 6.9 Hz), 6.58 (1H, b), 7.27 (1H, b), 8.28 (1H, b); ¹³C NMR (CDCl₃) & 14.0, 15.2, 18.7, 19.6, 21.1, 22.1, 22.2, 22.3, 22.6, 23.3, 23.9, 24.9, 25.7, 25.9, 26.5, 27.0, 31.2, 32.2, 32.4, 32.5, 40.0, 41.7, 42.4, 46.8, 52.5, 53.5, 53.9, 59.5, 70.0, 72.7, 81.0, 173.1, 173.4, 173.4, 175.0, 175.3; IR (film) 3288, 3081, 2958, 2872, 1644, 1538; MS (FAB) m/z 672 $[M+1]^+;$ HRMS calcd for $C_{33}H_{62}N_5O_7S$ $[M+1]^+$ 672.4371; found 672.4362.

Modeling of Compounds in BACE1. A 10 Å shell around the inhibitor in the BACE1 OM99-2 cocrystal structure (PDB ref 1FKN) was used for calculations. In this binding site model, the Monte Carlo docking/energy minimization protocol of the MCDOCK routine in the QXP program²⁶ (within the Flow96 package) was applied. Depending on the size and flexibility of the ligands, 1000 or 2000 search and energy minimization cycles were performed to ensure an in-depth conformational search and the exploration of different possible binding modes.

(26) McMartin, C.; Bohacek, R. S. J. Comput.-Aided Mol. Des. 1997, 11, 333.

Acknowledgment. We thank the National Science and Engineering Council of Canada (NSERC) and Novartis Pharma (Basel, Switzerland) for generous financial assistance. We also thank Dr. Michel Simard for X-ray crystallography of analogues and Eric Therrien for technical assistance.

Supporting Information Available: NMR spectra for the synthetic molecules and CIF files of X-ray structures **3a**, **4a**, **4c**, **5b**, **6c**, **9**, and **13**. X-ray crystallographic data have been deposited in the Cambridge Crystallographic Database. This material is available free of charge via the Internet at http://pubs.acs.org.

JO050749Y